Company Overview
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +83.99% |
| 6 Months: | -14.10% |
| 3 Months: | -10.94% |
| 1 Month: | -3.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross3d ago
- RSI (14)45.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 35.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PLRZ Polyrizon Ltd. PHARMA | 11.15 | -2.28 | $26.45M | 0.00% | -27.56% | -25.38% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 895.00K | 635.00K | 1.30M | 5.79M |
| Operating Income | -895.00K | -635.00K | -1.30M | -5.79M |
| EBITDA | -890.00K | -631.00K | -1.18M | -5.44M |
| Interest Expense | - | - | - | - |
| Pretax Income | -779.00K | -600.00K | -1.54M | -3.33M |
| Tax Provision | - | - | - | - |
| Net Income | -779.00K | -600.00K | -1.54M | -3.33M |
| Diluted EPS | -294.35 | -239.27 | -805.20 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 546.00K | 559.00K | 5.55M | 21.44M |
| Current Assets | 51.00K | 54.00K | 2.65M | 12.86M |
| Cash & Equivalents | 36.00K | 4.00K | 2.55M | 1.31M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 1.45M | 750.00K | 261.00K | 443.00K |
| Current Liabilities | 1.20M | 502.00K | 261.00K | 443.00K |
| Long Term Debt | - | - | - | - |
| Total Debt | 622.00K | 200.00K | - | - |
| Total Equity | -900.00K | -191.00K | 5.29M | 20.99M |
| Shares Outstanding | 2.80K | 2.80K | 2.80K | 1.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.13M | -537.00K | -1.15M | -4.53M |
| Investing Cash Flow | -3.00K | 0 | 29.00K | -16.53M |
| Financing Cash Flow | 648.00K | 505.00K | 3.67M | 19.81M |
| Capital Expenditure | -3.00K | - | - | -7.00K |
| Free Cash Flow | -1.14M | -537.00K | -1.15M | -4.54M |
| Net Change in Cash | -487.00K | -32.00K | 2.55M | -1.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 86.6% | 314.1% | -29.2% | -15.9% |
| ROCE % | 137.3% | -1,114.0% | -24.6% | -27.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | MMCAP International, Inc. SPC | 9.32% | 199.47K | $2.19M |
| 2 | HRT Financial LP | 1.00% | 21.36K | $234.78K |
| 3 | Caitong International Asset Management Co., Ltd | - | 11 | $120 |
| 4 | Morgan Stanley | - | 3 | $32 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLRZ
One investor puts about $4 million into Polyrizon - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbFFQb2V5d1l4U19TM2FvYmRvRWR3VkdJbEtGVUx4bzVhVEN4T2UzOU0wT2FqamhhV3FjRVlBbExxd3B3UTFKNUhRd25TVjZIYlZ6QjhzVEstTkp2eV9qWElVc3hIYWQ0NWoxU1dhQ2loTURmdUdsNEtpakE1anRZSjJBYi00dWhMN0p1Nj…
(PLRZ) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNZTNZbDFSeXBGa1NJMVdUMG5oclZhclN3R2dDNFlucmUtelJUMUlNNVVockpQSDhsTEQ2ZlpmQXhpY3Y4MHpwTTR6VDhPc0pIbFFWT2pKNUJubUNFQzNSOTJKRTZJMTFCUUUzV3VlaGh6U3M0cEtxZC1MYlE3WXAwTmY5MWEtWEdpa3c2YW…
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQR1JPT1lQRmVCeHFVM0JtMm45U2s4bV8yLUhmTG9lZ21QemhBYjRTZDd3MnpHel9iOEpYT3ZUbFhXNUVfRkNsSkpOeksteDNWVFhJRi05QzlreDZaZTlIUHVfZU5xb1I1Umkwb3ZldUdmSVlrd0p5TERsT2w2RVNraWIzTHBpalFHV0dvZ2…
One investor agreed to buy Polyrizon shares and warrants; proceeds are expected at about $4 million. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOQWR2WHJYUVYxRTRnUW5oYW1rTktFVUdwZzBjX3pOLXA4UEQyN0hLdHU0X05vRVpUUFNvOF9VUFBNZlhzN0FoQ3FRWkp4TkFqRHVwdFRueDM2VThtYWNIcmxDcS1NMWYzMUlTZmRXcF83eEtJNkd1b3Q5TW5FbTBCTWpTMUtTMlVSMDZmYU…
PLRZ - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4teFhORWVkOG9wR2plaGlUc21qUmJKYnJZX05YQm1Ta0swVWNOaWJBSmNRcmU0aEVMTU5laHkyVUM0OVFsWVE?oc=5" target="_blank">PLRZ</a> <font color="#6f6f6f">Finviz</font>…
PLRZ Stock Price and Chart — NASDAQ:PLRZ - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9mSmtCaHhlaV8ybGRGRGdnbkY1b2JXQVRZUXhGckxBSjhORTcwa2NiSk9SaGgxb1BsN3dJcjFtdnpFb2ZlbTczYmNKWTZkaGhhNWxDdW5JV3d3aldX?oc=5" target="_blank">PLRZ Stock Price and Chart — NASDAQ:PLRZ</a…
PLRZ — Frequently Asked Questions
What is the current share price of Polyrizon Ltd. (PLRZ)?
As of 2026-09-19 21:16 PDT, Polyrizon Ltd. (PLRZ) trades at $11.15 on NasdaqCM. Its 52-week range is $3.13 to $17.17.
What is the market capitalisation of PLRZ?
Polyrizon Ltd. (PLRZ) has a market capitalisation of $26.45M on NasdaqCM.
What is the P/E ratio of PLRZ?
PLRZ trades at a trailing price-to-earnings (P/E) ratio of -2.28. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.84.
What is the return on equity (ROE) of PLRZ?
PLRZ has a return on equity (ROE) of -25.38%. Its return on capital employed (ROCE) is -27.56%.
Is PLRZ a good stock to buy?
This page provides a data-driven analysis of Polyrizon Ltd. (PLRZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.